Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06594315 · ClinicalTrials.gov registry record
Assessing Brain Metabolism Using MRS With Deuterated Glucose
A clinical trial of Glioma, sponsored by University of California, San Francisco.
- Active
- Registry status
- 80
- Enrollment target
- 1
- Study location
NCT06594315 is a study of Glioma that is active but no longer recruiting, run by University of California, San Francisco. The registered enrollment target is 80 participants, below the 209-participant average among 87 other Glioma trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06594315, a study of Glioma, is active but no longer recruiting, sponsored by University of California, San Francisco.
- ACTIVE NOT RECRUITING
- Registry status
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will investigate the use of Hydrogen 1 (1H) magnetic resonance spectroscopy (MRS) with deuterated glucose (2H-glucose) to detect dynamic glucose uptake in the brain.
Conditions Studied
Interventions
- PROCEDURE Magnetic Resonance Imaging (MRI)
- PROCEDURE Blood Sample
- PROCEDURE MR spectroscopy (MRS)
- DRUG Deuterated Glucose
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2022-07-20 |
| Est. Completion | 2027-07-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06594315
The ClinicalTrials.gov registry entry for NCT06594315 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 209-participant average among 87 other Glioma trials with a reported enrollment target (62% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioma appearing as the primary indexed condition, and to 4 interventions - of which Magnetic Resonance Imaging (MRI) is the first listed.
NCT06594315 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06594315 about?
NCT06594315 is a clinical study titled "Assessing Brain Metabolism Using MRS With Deuterated Glucose". This study will investigate the use of Hydrogen 1 (1H) magnetic resonance spectroscopy (MRS) with deuterated glucose (2H-glucose) to detect dynamic glucose uptake in the brain.
What is the current status of trial NCT06594315?
This trial is currently active not recruiting. The enrollment target is 80 participants. The study started on 2022-07-20. Estimated completion is 2027-07-31.
What conditions does trial NCT06594315 study?
This clinical trial studies the following conditions: Glioma.
What interventions are being tested in trial NCT06594315?
The interventions under investigation include: Magnetic Resonance Imaging (MRI) (PROCEDURE), Blood Sample (PROCEDURE), MR spectroscopy (MRS) (PROCEDURE), Deuterated Glucose (DRUG).
Who is sponsoring clinical trial NCT06594315?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06594315 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
RECRUITING · Phase 2
-
Tumor Treating Fields for the Treatment of Brainstem Gliomas
RECRUITING · NA
-
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
RECRUITING · Phase 4
-
Cognitive Changes of IDH-mutant and IDH-wildtype Glioma Patients After Chemoradiotherapy With Radiation Dose to the Resting State Networks
RECRUITING
-
Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
RECRUITING · Phase 1
-
Sequential Treatments or Combinations Including Dasatinib, Quercetin, Fisetin and/or Temozolomide for the Treatment of Previously Treated Glioma With Residual Disease
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.